Regenerative Medicine

HomeRegenerative Medicine

Starting material quality is a risk factor for cell therapies in manufacturing and clinical outcomes

Introduction Cell therapies for regenerative medicine (Regen Med) and immunotherapies such as Chimeric Antigen Receptor (CAR)-T and Tumor Infiltrating Lymphocytes (TIL) cell therapies are breakthroughs...

More News

Starting material quality is a risk factor for cell therapies in manufacturing and clinical outcomes

Introduction Cell therapies for regenerative medicine (Regen Med) and immunotherapies such as Chimeric Antigen Receptor (CAR)-T and Tumor Infiltrating Lymphocytes (TIL) cell therapies are breakthroughs...

Challenges of Home Trial Services in Clinical Research

Clinical trials are essential to advancing medicine, yet participating in a study can place a considerable burden on patients. Frequent hospital visits, transportation challenges,...

Regenerative Medicine: Converging Innovation, Regulation, and the Future of Healing

A focused overview of scientific progress, manufacturing evolution, and regulatory transformation Regenerative medicine is transforming healthcare by aiming to restore, replace, or regenerate damaged...